Inflammatory monocyte gene signature predicts beneficial within group effect of simvastatin in patients with schizophrenia spectrum disorders in a secondary analysis of a randomized controlled trial

Addington, 1993, Assessing depression in schizophrenia: the calgary depression scale, Br. J. Psychiatry, suppl, 39, 10.1192/S0007125000292581 Akkouh, 2020, Decreased il-1β-induced ccl20 response in human ipsc-astrocytes in schizophrenia: potential attenuating effects on recruitment of regulatory t cells, Brain Behav. Immun., 87, 634, 10.1016/j.bbi.2020.02.008 Almulla, 2021, In schizophrenia, immune-inflammatory pathways are strongly associated with depressive and anxiety symptoms, which are part of a latent trait which comprises neurocognitive impairments and schizophrenia symptoms, J. Affect. Disord., 287, 316, 10.1016/j.jad.2021.03.062 Andreasen, 1992, The comprehensive assessment of symptoms and history (cash). An instrument for assessing diagnosis and psychopathology, Arch gen psychiatry, 49, 615, 10.1001/archpsyc.1992.01820080023004 Bates, 2014 Begemann, 2015, Simvastatin augmentation for recent-onset psychotic disorder: a study protocol, Bba clin, 4, 52, 10.1016/j.bbacli.2015.06.007 Beillard, 2003, Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (rq-pcr) - a europe against cancer program, Leukemia, 17, 2474, 10.1038/sj.leu.2403136 Bell, 1994, Dsm-iv: diagnostic and statistical manual of mental disorders, JAMA, 272, 828, 10.1001/jama.1994.03520100096046 Benros, 2011, Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study, Am J. Psychiatry., 168, 1303, 10.1176/appi.ajp.2011.11030516 Berman, 2009, Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants, CNS Spectr., 14, 197, 10.1017/S1092852900020216 Bishop, 2022, Inflammation subtypes and translating inflammation-related genetic findings in schizophrenia and related psychoses: a perspective on pathways for treatment stratification and novel therapies, Harv. Rev. Psychia., 30, 59, 10.1097/HRP.0000000000000321 Branchi, 2020, Brain-immune crosstalk in the treatment of major depressive disorder, Eur. Neuropsychopharmacol, 45, 89, 10.1016/j.euroneuro.2020.11.016 Cai, 2020, Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation, Mol. psychiatry, 25, 761, 10.1038/s41380-018-0235-x Çakici, 2019, An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis, Psychol. Med., 49, 2307, 10.1017/S0033291719001995 Cantù, 2021, Augmentation with atypical antipsychotics for treatment-resistant depression, J. Affect. Disord., 280, 45, 10.1016/j.jad.2020.11.006 Charlson, 2018, Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016, Schizophr. Bull., 44, 1195, 10.1093/schbul/sby058 Charrad, 2014, Nbclust: an r package for determining the relevant number of clusters in a data set, J. Stat. Software, 61, 1, 10.18637/jss.v061.i06 Chaudhry, 2014, Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study, Ther Adv. Psychopharmacol., 4, 110, 10.1177/2045125313511487 Chistiakov, 2015, Changes in transcriptome of macrophages in atherosclerosis, J. Cell Mol. Med., 19, 1163, 10.1111/jcmm.12591 Corya, 2006, A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression, Depress. Anxiety, 23, 364, 10.1002/da.20130 Counotte, 2018, Th17/t regulator cell balance and nk cell numbers in relation to psychosis liability and social stress reactivity, Brain Behav. Immun., 69, 408, 10.1016/j.bbi.2017.12.015 Cussotto, 2022, Low omega-3 polyunsaturated fatty acids predict reduced response to standard antidepressants in patients with major depressive disorder, Depress. Anxiety, 39, 407, 10.1002/da.23257 De hert, 2011, Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care, World Psychiatr., 10, 52, 10.1002/j.2051-5545.2011.tb00014.x Deakin, 2018, The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (benemin): a randomised, double-blind, placebo-controlled trial, Lancet Psychiatr., 5, 885, 10.1016/S2215-0366(18)30345-6 Di nicola, 2013, Serum and gene expression profile of cytokines in first-episode psychosis, Brain Behav. Immun., 31, 90, 10.1016/j.bbi.2012.06.010 Doncheva, 2019, Cytoscape stringapp: network analysis and visualization of proteomics data, J. Proteome Res., 18, 623, 10.1021/acs.jproteome.8b00702 Dorée, 2007, Quetiapine augmentation of treatment-resistant depression: a comparison with lithium, Curr. Med. Res. Opin., 23, 333, 10.1185/030079906X162809 Drexhage, 2011, An activated set point of t-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces, Int. J. Neuropsychopharmacol., 14, 746, 10.1017/S1461145710001653 Drexhage, 2011, The activation of monocyte and t cell networks in patients with bipolar disorder, Brain Behav. Immun., 25, 1206, 10.1016/j.bbi.2011.03.013 Drexhage, 2010, Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients, Int. J. Neuropsychopharmacol., 13, 1369, 10.1017/S1461145710000799 Dunleavy, 2022, Inflammation in first-episode psychosis: the contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis, Acta Psychiatr. Scand., 146, 6, 10.1111/acps.13416 Fillman, 2013, Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia, Mol. psychiatry, 18, 206, 10.1038/mp.2012.110 Fraguas, 2019, Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis, Schizophr. Bull., 45, 742, 10.1093/schbul/sby125 Frydecka, 2018, Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study, Brain Behav. Immun., 71, 28, 10.1016/j.bbi.2018.05.002 Ghanizadeh, 2014, Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial, Recent Pat. Inflamm. Allergy Drug Discov., 8, 211, 10.2174/1872213X08666141029123524 Goldsmith, 2016, A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression, Mol. psychiatry, 21, 1696, 10.1038/mp.2016.3 Grosse, 2015, Clinical characteristics of inflammation-associated depression: monocyte gene expression is age-related in major depressive disorder, Brain Behav. Immun., 44, 48, 10.1016/j.bbi.2014.08.004 Grosse, 2016, Deficiencies of the t and natural killer cell system in major depressive disorder: t regulatory cell defects are associated with inflammatory monocyte activation, Brain Behav. Immun., 54, 38, 10.1016/j.bbi.2015.12.003 Gu, 2016, Complex heatmaps reveal patterns and correlations in multidimensional genomic data, Bioinformatics, 32, 2847, 10.1093/bioinformatics/btw313 Hjorthøj, 2017, Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis, Lancet Psychiatr., 4, 295, 10.1016/S2215-0366(17)30078-0 Huet, 2021, Relationship between body mass index and neuropsychiatric symptoms: evidence and inflammatory correlates, Brain Behav. Immun., 94, 104, 10.1016/j.bbi.2021.02.031 Jääskeläinen, 2013, A systematic review and meta-analysis of recovery in schizophrenia, Schizophr. Bull., 39, 1296, 10.1093/schbul/sbs130 Jeppesen, 2020, Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders - a comprehensive systematic review and meta-analysis, Brain Behav. Immun., 90, 364, 10.1016/j.bbi.2020.08.028 Jon, 2013, Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study, Clin. Neuropharmacol., 36, 157, 10.1097/WNF.0b013e3182a31f3d Kay, 1987, The positive and negative syndrome scale (panss) for schizophrenia, Schizophr. Bull., 13, 261, 10.1093/schbul/13.2.261 Keitner, 2009, A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression, J. Psychiatr. Res., 43, 205, 10.1016/j.jpsychires.2008.05.003 Kelly, 2015, Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms, J. Clin. Psychopharmacol., 35, 374, 10.1097/JCP.0000000000000345 Kritharides, 2017, Cardiovascular disease in patients with schizophrenia, Med. J. Aust., 206, 91, 10.5694/mja16.00650 Lamers, 2019, Longitudinal association between depression and inflammatory markers: results from The Netherlands study of depression and anxiety, Biol psychiatry, 85, 829, 10.1016/j.biopsych.2018.12.020 Lee, 2017, Inflammation in schizophrenia: cytokine levels and their relationships to demographic and clinical variables, Am J. Geriatr. Psychiatry, 25, 50, 10.1016/j.jagp.2016.09.009 Lenth, 2019 Li, 2020, Prevalence of comorbid depression in schizophrenia: a meta-analysis of observational studies, J. Affect. Disord., 273, 524, 10.1016/j.jad.2020.04.056 Livak, 2001, Analysis of relative gene expression data using real-time quantitative pcr and the 2− δδct method, Methods, 25, 402, 10.1006/meth.2001.1262 Lynall, 2020, Peripheral blood cell-stratified subgroups of inflamed depression, Biol psychiatry, 88, 185, 10.1016/j.biopsych.2019.11.017 Marcus, 2008, The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study, J. Clin. Psychopharmacol., 28, 156, 10.1097/JCP.0b013e31816774f9 Martinuzzi, 2019, Correction: stratification and prediction of remission in first-episode psychosis patients: the optimise cohort study, Transl. Psychiatry, 9 Mcintyre, 2014, Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach, J. Affect. Disord., 156, 1, 10.1016/j.jad.2013.10.043 Meire, 2016 Miller, 2011, Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects, Biol psychiatry, 70, 663, 10.1016/j.biopsych.2011.04.013 Miller, 2013, Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects, Biol psychiatry, 73, 993, 10.1016/j.biopsych.2012.09.007 Monte, 2013, Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: possible involvement of antioxidant and nitrergic pathways, J. Psychopharmacol., 27, 1032, 10.1177/0269881113503506 Nettis, 2021, Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial, Neuropsychopharmacology, 46, 939, 10.1038/s41386-020-00948-6 Nielsen, 2021, Cardiovascular disease in patients with severe mental illness, Nat. Rev. Cardiol., 18, 136, 10.1038/s41569-020-00463-7 Nuñez, 2022, Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis, J. Affect. Disord., 302, 385, 10.1016/j.jad.2021.12.134 Padmos, 2008, A discriminating messenger rna signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes, Arch gen psychiatry, 65, 395, 10.1001/archpsyc.65.4.395 Pedersen, 2004, Simvastatin: a review, Expet Opin. Pharmacother., 5, 2583, 10.1517/14656566.5.12.2583 R core team, 2022 Raison, 2013, A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers, JAMA Psychiatr., 70, 31, 10.1001/2013.jamapsychiatry.4 Rapaport, 2006, Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation, Neuropsychopharmacology, 31, 2505, 10.1038/sj.npp.1301113 Robinson, 2015, The 2013 acc/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence, Eur. Heart J., 36, 2110, 10.1093/eurheartj/ehv182 Saetre, 2007, Inflammation-related genes up-regulated in schizophrenia brains, BMC Psychiatr., 7, 46, 10.1186/1471-244X-7-46 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 Schiweck, 2020, Childhood trauma, suicide risk and inflammatory phenotypes of depression: insights from monocyte gene expression, Transl. Psychiatry, 10, 296, 10.1038/s41398-020-00979-z Schlaaff, 2020, Increased densities of t and b lymphocytes indicate neuroinflammation in subgroups of schizophrenia and mood disorder patients, Brain Behav. Immun., 88, 497, 10.1016/j.bbi.2020.04.021 Shelton, 2001, A novel augmentation strategy for treating resistant major depression, Am J. Psychiatry., 158, 131, 10.1176/appi.ajp.158.1.131 Simon, 2021, Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 111, 10.1016/j.pnpbp.2021.110391 Singmann, 2015 Sneeboer, 2020, Increased number of t-lymphocytes in post-mortem brain tissue of patients with schizophrenia, Schizophr. Res., 216, 526, 10.1016/j.schres.2019.10.032 Snijders, 2016, A dynamic course of t cell defects in individuals at risk for mood disorders, Brain Behav. Immun., 58, 11, 10.1016/j.bbi.2016.05.007 Sommer, 2021, Simvastatin augmentation for patients with early-phase schizophrenia-spectrum disorders: a double-blind, randomized placebo-controlled trial, Schizophr. Bull., 47, 1108, 10.1093/schbul/sbab010 Sommer, 2020, The clinical course of schizophrenia in women and men-a nation-wide cohort study, Npj Schizophrenia, 6, 10.1038/s41537-020-0102-z Sommer, 2014, Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update, Schizophr. Bull., 40, 181, 10.1093/schbul/sbt139 Stancu, 2001, Statins: mechanism of action and effects, J. Cell Mol. Med., 5, 378, 10.1111/j.1582-4934.2001.tb00172.x Szklarczyk, 2021, The string database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets, Nucleic Acids Res., 49, d605, 10.1093/nar/gkaa1074 Tarantino, 2021, Natural killer cells in first-episode psychosis: an innate immune signature?, Mol. psychiatry, 26, 5297, 10.1038/s41380-020-01008-7 Vogels, 2017, T cell deficits and overexpression of hepatocyte growth factor in anti-inflammatory circulating monocytes of middle-aged patients with bipolar disorder characterized by a high prevalence of the metabolic syndrome, Front. Psychiatr., 8, 34, 10.3389/fpsyt.2017.00034 Volk, 2015, Molecular mechanisms and timing of cortical immune activation in schizophrenia, Am J. Psychiatry., 172, 1112, 10.1176/appi.ajp.2015.15010019 Weiser, 2021, Adjunctive aspirin vs placebo in patients with schizophrenia: results of two randomized controlled trials, Schizophr. Bull., 47, 1077, 10.1093/schbul/sbaa198 Weye, 2021, Register-based metrics of years lived with disability associated with mental and substance use disorders: a register-based cohort study in Denmark, Lancet Psychiatr., 8, 310, 10.1016/S2215-0366(21)00029-8